Platelet aggregation, dyslipoproteinemia and polyunsaturated fatty acids
Abstract
The article reviews the trials on the association between increased functional activity of platelets and platelet membrane polyunsaturated fatty acids (PUFA), PUFA in serum lipoprotein phospholipids, and dyslipoproteinemia (DLP) type and severity. Platelet structural and functional disturbances, often accompanying DLP and influenced by its type, affect platelet aggregation – via platelet membrane lipid modification, as well as via modified synthesis of platelet functional activity modulators (e.g., TxA2 ). Possible approaches to platelet hyperaggregation correction are discussed, including membrane lipid modulation via lipoprotein profile normalization during pharmaceutical and non-pharmaceutical treatment.
About the Authors
E. I. Sokolov
Moscow State Medico-Stomatological University. Moscow
Russian Federation
Russian Federation
V. A. Metelskaya
State Research Center for Preventive Medicine, State Federal Agency for Health and Social Development. Moscow
Russian Federation
Russian Federation
N. V. Perova
State Research Center for Preventive Medicine, State Federal Agency for Health and Social Development. Moscow
Russian Federation
Russian Federation
G. N. Shchukina
Moscow State Medico-Stomatological University. Moscow
Russian Federation
Russian Federation
V. M. Fomina
Moscow State Medico-Stomatological University. Moscow
Russian Federation
Russian Federation
References
1. Андреенко Г.В., Суворова Л.А. Роль липидов в функциональной активности тромбоцитов. Успехи соврем биол 1986; 101(3):436-48.
2. Ботолова Е.Н., Соловьев В.В., Семавин И.Е. и др. Связь агрегации тромбоцитов и их липидов со спектром липопротеидов плазмы крови при инфаркте миокарда. Клин мед 1986; 4: 54-8.
3. Ботолова Е.Н., Соловьев В.В., Озерова И.Н. и др. Влияние эссенциальных фосфолипидов на липидный спектр плазмы крови и агрегационную способность тромбоцитов у больных ишемической болезни сердца. Кардиология 1988; 9: 57-61.
4. Васютина Е.И, Метельская В.А., Ахмеджанов Н.М. и др. Сравнительное изучение гиполипидемического эффекта и влияния на агрегацию тромбоцитов аторвастатина и симвастатина у больных коронарной болезнью сердца, сахарным диабетом 2 типа и комбинированной гиперлипиедмией. Кардиология 2003; 1: 30-5.
5. Габбасов З.А., Попов Е.Г., Гаврилов И.Ю. и др. Новый высокочувствительный метод анализа агрегации тромбоцитов. Лаб дело 1989; 10: 15-8.
6. Жук М.Ю., Метельская В.А., Перова Н.В. и др. Нарушения плазменно-тромбоцитарного звена гемостаза у больных с сочетанием артериальной гипертонии и гиперлипидемии. РКЖ 2003; 5: 11-7.
7. Зыкова В.П., Перова Н.В., Калинкина О.М. Исследование генерации ин витро тромбоксана А2 тромбоцитами у больных с впервые возникшей стенокардией под влиянием рыбной диеты. Кардиология 1990; 10: 24-7.
8. Калинкина О.М., Влияние диеты, обогащенной омега-3-полиненасыщенными ирными кислотами, на функциональную активность тромбоцитов и липидно-аполипопротеиновый спектр крови при впервые возникшей стенокардии. Тер архив 1990; 9: 77-83.
9. Озерова И.Н., Герасимова Е.Н., Чазова Л.В. Активность аденилатциклазы в тромбоцитах у больных ишемической болезнью сердца. Тер архив 1975; 7: 72-7.
10. Панченко Е.П. Механизмы развития острого коронарного синдрома. РМЖ 2000; 8: 359-64.
11. Adan Y, Shibata K, Sato M, et al. Effects of docosahexaenoic and eicosapentaenoic acid on lipid metabolism, eicosanoid production, platelet aggregation and atherosclerosis in hypercholesterolemic rats. Biosci Biotechnol Biochem 1999; 63: 111-9.
12. Becker RC. Seminars in thrombosis, thrombolysis and vascular biology platelet activity in cardiovascular disease. Cardiology 1991; 79: 49-63.
13. Beitz A, Nikitina NA, Giessler Ch, et al. Modulation of TXA2 generation of platelets by human lipoproteins. Prostaglan Leukotr & Ess Fatty Acids 1990; 40: 57-61.
14. Born GVR. Quantitative investigation into the aggregation of blood platelets. J Physiol 1962; 162: 67-8.
15. Breddin HK, Lippold R, Bittner M, et al. Spontaneous platelet aggregation as a predictive risk factor for vascular occlusions in healthy volunteers? Results of the HAPARG Study. Haemostatic parameters as risk factors in healthy volunteers. Atherosclerosis 1999; 144: 211-9.
16. Cerbone AM, Cirillo F, Coppola A, et al. Persistent impairment of platelet aggregation following cessation of a short-course dietary supplementation of moderate amounts of N-3 fatty acid ethyl esters. Thromb Haemost 1999; 8: 128-33.
17. Di Stasi D, Bernasconi R, Marchioli R, et al. Early modifications of fatty acid composition in plasma phospholipids, platelets and mononucleates of healthy volunteers after low doses of n-3 polyunsaturated fatty acids. Eur J Clin Pharmacol 2004; 60: 183-90.
18. Elwood PC, Renaud S, Beswick AD, et al. Platelet aggregation and incident ischaemic heart disease in the Caerphilly cohort. Heart 1998; 80: 578-82.
19. Ferroni P, Basili S, Davi G. Platelet activation, inflammatory mediators and hypercholesterolemia. Cuur Vasc Pharmacol 2003; 1: 157-69.
20. Frohlich J, Steiner G. Dyslipidaemia and coagulation defects of insulin resistance. Int J Clin Pract Suppl 2000; 113: 14-22.
21. GISSI – Prevenzione Investigators Dietary Supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of GISSI-Prevenzione trial. Lancet 1999; 354: 447-55.
22. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 72: 2294-8.
23. Hanson J, Rolin S, Reynaud D, et al. In vitro and in vivo pharmacological characterization of BM-613, a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist. J Pharmacol Exp Ther 2005; 313: 293-301.
24. Hirsh PD, Hillis LD, Campbell WB, et al. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med 1981; 304: 685-91.
25. Imano H, Iso H, Sato S, et al. Determinants of platelet aggregation in 50-70-year-old men from three Japanese communities. Atherosclerosis 2002; 165: 327-34.
26. Jung YS, Kim MH, Lee SH, et al. Antithrombotic effect of onion in streptozotocin-induced diabetic rat. Prostaglan Leuk Ess Fatty Acids 2002; 66: 453-8.
27. Kalinowski L, Matys T, Chabielska E, et al. Angiotensin II AT1 receptor antagonist inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension 2002; 40: 521-7.
28. Kang JX, Leaf A. Evidence that free polyunsaturated fatty acids modify Na+ channels by directly binding of the channel proteins. Proc Natl Acad Sci USA, 1996; 93: 3542-6.
29. Li D, Zhang H, Hsu-Hage BH, et al. The influence of fish, meat and polyunsaturated fat intakes on platelet phospholipid polyunsaturated fatty acids in male Melbourne Chinese and Caucasian. Eur J Clin Nutr 2001; 55: 1036-42.
30. Marcus AJ. The eicosanoids in biology and medicine. J Lipid Res 1984; 25: 1511-6.
31. McGill DA, Ardlie NG. Abnormal platelet reactivity in men with premature coronary heart disease. Coron Artery Dis 1994; 5: 889-900.
32. Michibayashi T. Platelet aggregation and vasoconstriction related of platelet cyclooxygenase and 12-lipoxygenase pathways. J Atheroscl Thromb 2005; 12: 154-62.
33. Miller GJ. Lipoprotein and the haemostatic system in atherothrombotic disorders. Baill Clin Haemotol 1994; 7: 713-32.
34. Motyka M, Hartwich J, Skrzeczynska J, et al. Lipoprotein composition related to metabolic syndrome as parameters influencing platelet adhesion. Atherosclerosis 2004; 5: 98-103.
35. Nassar T, Sachais BS, Akkawi S, et al. Platelet factor 4 enhances the binding of oxidized low-density lipoprotein to vascular wall cells. J Biol Chem 2003; 278: 6187-93.
36. Nordoy A. Lipids as triggering factors in thrombosis. Thromb Haemost 1976; 35: 32-48.
37. Notarbartolo A, Davi G, Averna M, et al. Inhibition of Thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscl Thromb Vasc Biol 1995; 15: 247-51.
38. O’Brien JR. Platelet aggregation. Part II. Some results from a new study. J Clin Pathol 1962; 15: 247-51.
39. Riddel DR, Owen JS. Nitric oxide and platelet aggregation. Vitam Horm 1999; 57: 25-48.
40. Shafer AI. Antiplatelet therapy Am J Med 1996; 101: 199-209.
41. Thomson M, Mustafa T, Ali M. Thromboxane-B(2) levels in serum of rabbits receiving a single intravenous dose of aqueous extract of garlic and onion. Prostaglan Leuk Ess Fatty Acids 2000; 63: 217-21.
42. Tremoli E, Camera M, Toschi V, Colli S. Tissue factor in atherosclerosis. Atherosclerosis 1999; 144: 273-83.
43. Volf I, Roth A, Moeslinger T, et al. Stimulating effect of biologically modified low density lipoproteins on ADP-induced aggregation of washed platelets persists in absence of specific binding. Thromb Res 2000; 97: 441-9.
44. Wang Z, Huang Y, Zou J, et al. Effects of red wine and wine polyphenol resveratrol on platelet aggregation in vivo and in vitro. Int J Mol Med 2002; 9: 77-9.
45. Wu JM, Wang ZR, Hsieh TC, et al. Mechanism of cardioprotection by resveratrol, a phenolic antioxidant present in red wine. Int J Mol Med 2001; 8: 3-17.
Review
For citations:
Sokolov E.I., Metelskaya V.A., Perova N.V., Shchukina G.N., Fomina V.M. Platelet aggregation, dyslipoproteinemia and polyunsaturated fatty acids. Cardiovascular Therapy and Prevention. 2006;5(5):87-93. (In Russ.)
Views:
660
Email this article 
